-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Initiates Coverage On Bicara Therapeutics with Neutral Rating, Announces Price Target of $18

Benzinga·12/18/2025 09:34:30
Listen to the news
Mizuho analyst Joseph Catanzaro initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Neutral rating and announces Price Target of $18.